Skip to content
deferiprone

Structure via PubChem · Public domain (PubChem)

EntityQ749664· pop 20· linked from 50 articles

deferiprone

Sign in to save

Also known as APO-66, CP20, Ferriprox®, 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone, 1,2-Dimethyl-3-hydroxypyrid-4-one, Deferiproni, PL-1, APO-066

Deferiprone, sold under the brand name Ferriprox among others, is a medication that chelates iron and is used to treat iron overload in thalassaemia major. It was first approved and indicated for use in treating thalassaemia major in 1994 and had been licensed for use in the European Union for many years while awaiting approval in Canada and in the United States. On 14 October 2011, it was approved for use in the US under the FDA's accelerated approval program.

Key facts

Drug.Verifiedfields
changed
Drug.Watchedfields
changed
Drug.verifiedrevid
443270530
Drug.image
Deferiprone.svg
Drug.image_class
skin-invert-image
Drug.width
120
Drug.tradename
Ferriprox
Drug.MedlinePlus
a612016
Drug.DailyMedID
Deferiprone
Drug.pregnancy_AU
D
Drug.routes_of_administration
By mouth
Drug.ATC_prefix
V03
Drug.ATC_suffix
AC02
Drug.legal_AU
S4
Drug.legal_CA
Rx-only
Drug.legal_UK
POM
Drug.legal_UK_comment
/ P
Drug.legal_US
Rx-only

via Wikipedia infobox

Chemical data

Formula
C7H9NO2
Molecular weight
139.15 g/mol
IUPAC name
3-hydroxy-1,2-dimethylpyridin-4-one
SMILES
CC1=C(C(=O)C=CN1C)O
InChIKey
TZXKOCQBRNJULO-UHFFFAOYSA-N
XLogP
0.5
Polar surface area
40.5 Ų
H-bond donors
1
H-bond acceptors
3
Formal charge
0

via PubChem

Wikidata facts

Mass
139.063
Show 4 more facts
chemical formula
C₇H₉NO₂
canonical SMILES
CC1=C(C(=O)C=CN1C)O
World Health Organisation international non-proprietary name
deferiprone
Commons category
Deferiprone
Sources (5)

via Wikidata · CC0

~3 min read

Article

4 sections
Contents
  • Medical uses
  • Controversy
  • History
  • References

Deferiprone, sold under the brand name Ferriprox among others, is a medication that chelates iron and is used to treat iron overload in thalassaemia major. It was first approved and indicated for use in treating thalassaemia major in 1994 and had been licensed for use in the European Union for many years while awaiting approval in Canada and in the United States. On 14 October 2011, it was approved for use in the US under the FDA's accelerated approval program.

The most common side effects include red-brown urine (showing that iron is being removed through the urine), nausea (feeling sick), abdominal pain (stomach ache) and vomiting. Less common but more serious side effects are agranulocytosis (very low levels of granulocytes, a type of white blood cell) and neutropenia (low levels of neutrophils, a type of white blood cell that fights infections).

Connections

Categories